Omeros Corporation Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Omeros Corporation Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA

Maxim Positive on Omeros' (OMER) Omidria, OMS721; Reaffirms at 'Buy'

March 8, 2016 12:21 PM EST

Maxim reaffirms Omeros (Nasdaq: OMER) at 'Buy' following Q4 results and initiation of its Phase 3 OMS721 program for the treatment of atypical hemolytic uremic syndrome... More